HaploX is a leading genetic testing solutions provider in China with a focus on gene sequencing, liquid biopsies, bioinformatics and big data analytics. It is recognized as National High and New Technology Enterprise, and National Specialized and New 'Small Giant' Enterprise. Driven by our passion for technological innovation to benefit humanity, we are dedicated to becoming a prominent life science company in China.

Our labs in Shenzhen are certified by the best practice guidelines for genetic testing laboratories in the U.S., EU and China, including accreditations from the CAP (College of American Pathologists), CLIA (Clinical Laboratory Improvement Amendments), EMQN (European Molecular Genetics Quality Network) and NCCL (National Center for Clinical Laboratories). We pride ourselves in our ability to serve a wide range of genetic testing applications covering different population groups, tumor types and stages in the disease lifecycle. This includes providing clinically valuable genetic testing results that enable full cycle health management for cancer and other patients, health screening and risk assessment, as well as pathogenic microbe genetic testing. As of now, HaploX has provided genetic testing services and comprehensive solutions to hundreds of Class IIIA hospitals, biopharmaceutical companies, research institutes, health examination centers, insurance companies and local governments across China.